Presented by Nature Biotechnology, Produced with Support from Lonza
Originally Aired on 20 September 2017
The efficacy of CAR-T cells in acute lymphoblastic leukemia has ignited the field, as researchers and clinicians move to advance the technology. T cells, obtained from the patient and engineered to express a chimeric antigen receptor (CAR) that mediates antigen recognition and cellular activation, can kill tumor cells within days. The approach promises to expand to a broad range of tumors and antigens, with dozens of clinical trials now ongoing and FDA approval expected soon.
In recent months, ground has been gained towards identifying suitable target antigens beyond CD19, overcoming suppression in the microenvironment of solid tumors, and developing strategies to deal with antigen escape. Advances in clinical development, including efforts to develop a universal T cell line, identifying the best T cell subsets and managing side effects, will help reach patients outside a few academic centers. Looking beyond CAR-T cells, CAR-expressing NK and ϒδ T cells for cancer and CAAR-T cells for autoimmunity may represent promising approaches.
Watch this 60-minute free webinar and learn about the latest advances and outstanding challenges in the fast paced research environment of CARs with experts that bridge the lab and clinic.
Speakers:
- Marcela Maus, Assistant Professor, Harvard Medical School
- Renier Brentjens, Associate Member, Memorial Sloan Kettering Cancer Center
- Martin Pule, Clinical Senior Lecturer, University College London
Non-viral CAR-T Cell Generation:
- Efficient transfection of primary T cells using Lonza's Nucleofector® Technology
